Mesenchymal stem cells for bone repair and metabolic bone diseases. Export

@article{citeulike:6021564, abstract = {Human mesenchymal stem cells offer a potential alternative to embryonic stem cells in clinical applications. The ability of these cells to self-renew and differentiate into multiple tissues, including bone, cartilage, fat, and other tissues of mesenchymal origin, makes them an attractive candidate for clinical applications. Patients who experience fracture nonunion and metabolic bone diseases, such as osteogenesis imperfecta and hypophosphatasia, have benefited from human mesenchymal stem cell therapy. Because of their ability to modulate immune responses, allogeneic transplant of these cells may be feasible without a substantial risk of immune rejection. The field of regenerative medicine is still facing considerable challenges; however, with the progress achieved thus far, the promise of stem cell therapy as a viable option for fracture nonunion and metabolic bone diseases is closer to reality. In this review, we update the biology and clinical applicability of human mesenchymal stem cells for bone repair and metabolic bone diseases.}, author = {Undale, Anita H. and Westendorf, Jennifer J. and Yaszemski, Michael J. and Khosla, Sundeep}, citeulike-article-id = {6021564}, citeulike-linkout-0 = {http://dx.doi.org/10.4065/84.10.893}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19797778}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19797778}, citeulike-linkout-3 = {http://scholar.google.com/scholar?cluster=546321343006971647}, comment = {all KHOSLA * http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=PureSearch\&db=pubmed\&term=\%28khosla\%20s[Author]\%20AND\%20mayo[All\%20Fields]\%29}, doi = {10.4065/84.10.893}, issn = {1942-5546}, journal = {Mayo Clinic proceedings. Mayo Clinic}, keywords = {msc\_clinical, msc\_osteo, revu}, month = {October}, number = {10}, pages = {893--902}, posted-at = {2009-10-28 18:13:20}, priority = {2}, title = {Mesenchymal stem cells for bone repair and metabolic bone diseases.}, url = {http://dx.doi.org/10.4065/84.10.893}, volume = {84}, year = {2009} }

TY - JOUR ID - citeulike:6021564 L3 - citeulike-article-id:6021564 N2 - Human mesenchymal stem cells offer a potential alternative to embryonic stem cells in clinical applications. The ability of these cells to self-renew and differentiate into multiple tissues, including bone, cartilage, fat, and other tissues of mesenchymal origin, makes them an attractive candidate for clinical applications. Patients who experience fracture nonunion and metabolic bone diseases, such as osteogenesis imperfecta and hypophosphatasia, have benefited from human mesenchymal stem cell therapy. Because of their ability to modulate immune responses, allogeneic transplant of these cells may be feasible without a substantial risk of immune rejection. The field of regenerative medicine is still facing considerable challenges; however, with the progress achieved thus far, the promise of stem cell therapy as a viable option for fracture nonunion and metabolic bone diseases is closer to reality. In this review, we update the biology and clinical applicability of human mesenchymal stem cells for bone repair and metabolic bone diseases. IS - 10 JF - Mayo Clinic proceedings. Mayo Clinic SN - 1942-5546 EP - 902 TI - Mesenchymal stem cells for bone repair and metabolic bone diseases. VL - 84 SP - 893 KW - msc_clinical KW - msc_osteo KW - revu N1 - all KHOSLA * http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=PureSearch&db=pubmed&term=%28khosla%20s[Author]%20AND%20mayo[All%20Fields]%29 AU - Undale, Anita AU - Westendorf, Jennifer AU - Yaszemski, Michael AU - Khosla, Sundeep PY - 2009/10// UR - http://dx.doi.org/10.4065/84.10.893 ER -